RESUMO
A series of chemotherapeutic drugs that induce DNA damage, such as cisplatin (DDP), are standard clinical treatments for ovarian cancer, testicular cancer, and other diseases that lack effective targeted drug therapy. Drug resistance is one of the main factors limiting their application. Sensitizers can overcome the drug resistance of tumor cells, thereby enhancing the antitumor activity of chemotherapeutic drugs. In this study, we aimed to identify marketable drugs that could be potential chemotherapy sensitizers and explore the underlying mechanisms. We found that the alcohol withdrawal drug disulfiram (DSF) could significantly enhance the antitumor activity of DDP. JC-1 staining, propidium iodide (PI) staining, and western blotting confirmed that the combination of DSF and DDP could enhance the apoptosis of tumor cells. Subsequent RNA sequencing combined with Gene Set Enrichment Analysis (GSEA) pathway enrichment analysis and cell biology studies such as immunofluorescence suggested an underlying mechanism: DSF makes cells more vulnerable to DNA damage by inhibiting the Fanconi anemia (FA) repair pathway, exerting a sensitizing effect to DNA damaging agents including platinum chemotherapy drugs. Thus, our study illustrated the potential mechanism of action of DSF in enhancing the antitumor effect of DDP. This might provide an effective and safe solution for combating DDP resistance in clinical treatment.
Assuntos
Feminino , Masculino , Humanos , Cisplatino/farmacologia , Dissulfiram/farmacologia , Neoplasias Testiculares/tratamento farmacológico , Anemia de Fanconi/tratamento farmacológico , Alcoolismo/tratamento farmacológico , Resistencia a Medicamentos Antineoplásicos , Linhagem Celular Tumoral , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Apoptose , Antineoplásicos/uso terapêutico , Proliferação de CélulasRESUMO
Se presentan tres casos de anemia de Fanconi, atendidos en la Unidad de Hematologia del Hospital Universitario Ramon Gonzalez Valencia con edades al momento de diagnostico entre 6 y 13 anos, dos de sexo femenino, dos eran hermanos. Todos presentaban baja talla para la edad y malformaciones congenitas diversas. Todos los pacientes recibieron tratamiento con esteroides y androgenos. Un paciente fallecio despues de diez anos de evolucion, por sepsis y otro fallecio tras ocho anos de evolucion, por hemorragia masiva. El tercer paciente se encuentra actualmente en control. Se hace una breve revision de la literatura